Regenxbio Inc. (NASDAQ: RGNX) is a leading biotechnology company that focuses on the development of innovative gene therapies. These therapies are designed to be one-time treatments for a variety of serious diseases. The company's work often centers on rare genetic conditions that currently have limited or no treatment options available for patients.
The main theme is the recent optimism surrounding Regenxbio Inc. On June 22, 2026, analyst Brian Skorney of Robert W. Baird raised the stock price target for Regenxbio Inc. to $32.00. At the time, the stock's price was $8.91, which shows a significant potential increase based on this new projection from the analyst, highlighting positive RGNX stock analysis.
This positive outlook is supported by recent regulatory developments. Regenxbio Inc. announces it has aligned with the U.S. Food and Drug Administration (FDA) on a path for accelerated FDA approval of its gene therapy, Navsunli. This treatment is a potential one-time therapy for Mucopolysaccharidosis II (MPS II), an ultra-rare neurodegenerative disease, representing a significant step in rare disease treatment.
Following an appeal, the FDA now confirms that no new studies are needed for the therapy's approval. As highlighted by PR Newswire, the agency will review existing long-term data on an expedited basis. Regenxbio Inc. expects to resubmit its Biologics License Application (BLA) in the third quarter of 2026. A BLA is a request for permission to introduce a biologic product into the market.
The market reacts positively to this news, signaling strong biotech investment interest. The stock price for Regenxbio Inc. increased by 13.97% to $8.89, with a daily trading volume of over 5.43 million shares. This activity brings the company's market capitalization, which is the total value of all its shares, to approximately $459.59 million.
